Invesco’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1M | Buy |
720,139
+50,949
| +8% | +$70K | ﹤0.01% | 2859 |
|
|
2025
Q4 | $1.08M | Sell |
669,190
-1,731,567
| -72% | -$3.63M | ﹤0.01% | 2874 |
|
|
2025
Q3 | $6.55M | Buy |
2,400,757
+2,018,547
| +528% | +$6.71M | ﹤0.01% | 2087 |
|
|
2025
Q2 | $1.39M | Buy |
382,210
+121,607
| +47% | +$334K | ﹤0.01% | 2724 |
|
|
2025
Q1 | $500K | Buy |
260,603
+139,957
| +116% | +$286K | ﹤0.01% | 3148 |
|
|
2024
Q4 | $229K | Buy |
120,646
+872
| +0.7% | +$1.51K | ﹤0.01% | 3492 |
|
|
2024
Q3 | $158K | Sell |
119,774
-10,012
| -8% | -$13.4K | ﹤0.01% | 3559 |
|
|
2024
Q2 | $132K | Buy |
129,786
+103,951
| +402% | +$128K | ﹤0.01% | 3714 |
|
|
2024
Q1 | $47.3K | Sell |
25,835
-3,336
| -11% | -$5.33K | ﹤0.01% | 3806 |
|
|
2023
Q4 | $36.2K | Buy |
29,171
+5,353
| +22% | +$5.46K | ﹤0.01% | 3779 |
|
|
2023
Q3 | $27.2K | Sell |
23,818
-8,174
| -26% | -$10.5K | ﹤0.01% | 3842 |
|
|
2023
Q2 | $29.3K | Buy |
+31,992
| New | +$30.9K | ﹤0.01% | 3849 |
|
|
2023
Q1 | – | Sell |
-245,507
| Closed | -$142K | – | 3864 |
|
|
2022
Q4 | $142K | Sell |
245,507
-5,017
| -2% | -$1.57K | ﹤0.01% | 3772 |
|
|
2022
Q3 | $79K | Sell |
250,524
-14,026
| -5% | -$5.5K | ﹤0.01% | 3870 |
|
|
2022
Q2 | $93K | Sell |
264,550
-15,408
| -6% | -$6.46K | ﹤0.01% | 3900 |
|
|
2022
Q1 | $201K | Buy |
279,958
+89,594
| +47% | +$192K | ﹤0.01% | 3772 |
|
|
2021
Q4 | $431K | Sell |
190,364
-12,021
| -6% | -$32.8K | ﹤0.01% | 3451 |
|
|
2021
Q3 | $583K | Buy |
202,385
+15,163
| +8% | +$43.3K | ﹤0.01% | 3358 |
|
|
2021
Q2 | $710K | Buy |
187,222
+26,111
| +16% | +$87.9K | ﹤0.01% | 3272 |
|
|
2021
Q1 | $546K | Buy |
161,111
+131,414
| +443% | +$473K | ﹤0.01% | 3309 |
|
|
2020
Q4 | $83K | Sell |
29,697
-576,649
| -95% | -$1.68M | ﹤0.01% | 3666 |
|
|
2020
Q3 | $1.52M | Sell |
606,346
-486,094
| -44% | -$4.27M | ﹤0.01% | 2615 |
|
|
2020
Q2 | $14.8M | Sell |
1,092,440
-42,816
| -4% | -$443K | 0.01% | 1417 |
|
|
2020
Q1 | $8.61M | Buy |
+1,135,256
| New | +$8.83M | ﹤0.01% | 1598 |
|
|
2019
Q2 | – | Sell |
-1,141,290
| Closed | -$9.35M | – | 3715 |
|
|
2019
Q1 | $9.35M | Buy |
+1,141,290
| New | +$7.83M | ﹤0.01% | 1613 |
|
|
2018
Q2 | – | Sell |
-32,152
| Closed | -$306K | – | 3874 |
|
|
2018
Q1 | $306K | Sell |
32,152
-165,021
| -84% | -$2.31M | ﹤0.01% | 3494 |
|
|
2017
Q4 | $2.93M | Sell |
197,173
-390,759
| -66% | -$6.48M | ﹤0.01% | 2318 |
|
|
2017
Q3 | $11.6M | Buy |
587,932
+467,354
| +388% | +$7.19M | ﹤0.01% | 1480 |
|
|
2017
Q2 | $1.73M | Buy |
+120,578
| New | +$1.53M | ﹤0.01% | 2667 |
|
|
2016
Q2 | – | Sell |
-68,611
| Closed | -$618K | – | 3681 |
|
|
2016
Q1 | $618K | Buy |
+68,611
| New | +$556K | ﹤0.01% | 3153 |
|
|
2015
Q3 | – | Sell |
-569
| Closed | -$6K | – | 3787 |
|
|
2015
Q2 | $6K | Buy |
+569
| New | +$4.85K | ﹤0.01% | 4103 |
|
Other funds holding AKBA
VCM
VPM
Invesco's AKBA Position: Q1 2026 in Review
Invesco increased its Akebia Therapeutics (AKBA) stake by 7.6% in Q1 2026, buying an estimated $70K and bringing the position to 720,139 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #2859.
Invesco first reported a position in AKBA in Q2 2015 and has held it in 31 quarters since. The position peaked at $14.8M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Invesco held 720,139 shares of Akebia Therapeutics worth $1M as of Q1 2026.
- Invesco bought 50,949 Akebia Therapeutics shares in Q1 2026, an estimated $70K.
- Akebia Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2859 holding.
- Invesco first reported a position in Akebia Therapeutics in Q2 2015 and has held it in 31 quarters since.
- Invesco's Akebia Therapeutics position peaked at $14.8M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.